Clinical Trial for Plaque Psoriasis Patients May Prove to Offer Immediate Relief

Wednesday, August 10, 2016 Clinical Trials News J E 4
Seven slots available for patients suffering from painful skin disease

TAMPA, Fla., Aug. 10, 2016 /PRNewswire/ -- Adults who suffer from moderate-to-severe plaque psoriasis have a potential opportunity to join a new clinical trial that could revolutionize treatment for patients. Tampa dermatologist, Seth Forman, M.D., with Forward Clinical Trials (FCT), is leading the study of the investigational drug developed to relieve the symptoms of plaque psoriasis, a severe skin condition that appears as raised red patches and are often itchy and painful.

Plaque psoriasis is the most common form of psoriasis, affecting approximately 80 percent of the 7.5 million Americans who suffer from psoriasis. The patches are typically found on the scalp, knees and elbows, although any area of the skin can be involved. "This is a disease that is chronic and historically has been tough to treat," says Forman, principal investigator of FCT and an internationally recognized expert on the treatment of psoriasis and other auto-immune skin diseases. "We're honored to be selected to conduct a study that could ultimately help those who have suffered with this unmanageable disease for a long time," he added.  Plaque psoriasis is a disorder of the immune system and can occur at any age. It can be genetic and results from an overactive immune system.

Forman is also currently conducting trials for eczema, psoriasis and psoriatic arthritis. Patients interested in the trial can learn more and apply by visiting or calling (813) 264-2155.

About Forward Clinical Trials:

Forward Clinical Trials (FCT) is a multi-specialty clinical trials practice that provides new, innovative medicines of the future. FCT is located in Tampa, Fla. It is led by Seth B. Forman, M.D., a board-certified dermatologist and founder of Forman Dermatology & Skin Cancer Institute. Founded in 2012, FCT is a multispecialty research site conducting Phase II – IV studies. FCT participates in trials involving investigational and FDA-approved drugs.  For more information, visit us at or on Facebook.

Media Contacts:Molly CollinsEmail(850) 559-7107Jeannie SalamehEmail(727) 644-5010

To view the original version on PR Newswire, visit:

SOURCE Forward Clinical Trials



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Retirement Hack: Seniors Cash in on Cheap Dental C...
Identifying Newest Cannabis Strains for Cancer Tre...